



NEWS RELEASE

US Patent and Trademark Office Allows Patent on Defyrus' Breakthrough Broad Spectrum Antiviral Drug (DEF201)

Web Site Release

October 4, 2012

Toronto - Defyrus Inc. today announced that the U.S. Patent and Trademark Office ("USPTO") has allowed a key patent covering its broad spectrum anti-viral drug, DEF201. The patent is entitled "*Administration of Interferon for Prophylaxis against or Treatment of Pathogenic Infection*". DEF201 is an immunotherapy which supplements and enhances the body's native immune system thereby preventing infections or immediately combating ongoing viral or bacterial infections. This broad spectrum capability means that DEF201 is effective in treating many different diseases and represents a major advance over today's vaccines or antiviral drugs which are effective against only one disease.

"We are extremely pleased that the USPTO has allowed this significant patent covering our broad spectrum anti-viral technology. This patent recognizes Defyrus' innovative products and their application to managing a wide range of viral outbreaks of concern to public health & biodefense agencies worldwide" said Dr. Jeffrey Turner, President & CEO. "Our discovery is at the heart of modern infectious disease control and mitigation, because one drug can treat many bugs".

DEF201 is second generation interferon therapy that produces an antiviral state for 8-12 weeks via a single dose of intranasal mist. Such performance represents an advance over traditional interferon therapy, where recombinant IFN protein (rIFN) must be repeatedly injected every few days to be effective. Where rIFN therapy is restricted to hospital/clinical settings, this patented DEF201 innovation allows for large scale medical intervention to combat infectious disease in public health and biodefense worldwide. To date, >70 in vivo efficacy studies have confirmed DEF201's utility - as a monotherapy - in preventing or treating infectious viruses including: Ebola, Lassa, SARS, Yellow fever, Pox, Pichinde, Punta Toro and Eastern, Western, Venezuelan Equine Encephalitis (EEE, WEE, VEE).

DEF201 further enhances and potentiates the protective effects of other drugs such as monoclonal antibodies (MAbs) or vaccines when administered together. The benefits of combination therapy are realized with vaccine dose sparing, faster acquired immunity, and/or synergistic augmentation of MAbs, which reduces drug cost and speeds resolution of the infections.

"DEF201's manufacturing process development is complete, with cGMP drug now available for clinical evaluation. Further, our collaborations with senior infectious disease experts have produced six peer-reviewed publications which show extensive in vivo efficacy" said co-inventor Jane Ennis, Senior Project Manager, "our preclinical safety/toxicity studies are progressing well and should enable Defyrus to submit an IND to the US FDA and a CTA to Health Canada within 12-18 months".



About Defyrus

Defyrus is a private, life sciences biodefence company that collaborates with public health & biodefence R&D partners in the United States, United Kingdom, Singapore and Canada to develop and manufacture broad spectrum anti-viral drugs, MAbs and vaccines as effective medical countermeasures to treat viral-based diseases worldwide. www.defyrus.com

###

For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com